BTK and B-cell chronic lymphocytic leukemia: The effect of DNPEP inhibition on the drug sensitivity of primary, patient-derived CLL cells was also tested using ABT737 and two kinase inhibitors, the PI3K inhibitor, idelalisib, and the BTK inhibitor, ibrutinib (Figure 5C–E).